Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Telix Pharmaceuticals Limited (TLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.19
1 Year Target Price $20.19
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.41% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.23B USD | Price to earnings Ratio 173.44 | 1Y Target Price 20.19 |
Price to earnings Ratio 173.44 | 1Y Target Price 20.19 | ||
Volume (30-day avg) 2 | Beta 2.38 | 52 Weeks Range 13.61 - 30.36 | Updated Date 06/19/2025 |
52 Weeks Range 13.61 - 30.36 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.62% | Operating Margin (TTM) 9.49% |
Management Effectiveness
Return on Assets (TTM) 7.97% | Return on Equity (TTM) 20.49% |
Valuation
Trailing PE 173.44 | Forward PE 77.52 | Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 |
Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 12.96 | Enterprise Value to EBITDA 113.13 | Shares Outstanding 334724000 | Shares Floating 282348658 |
Shares Outstanding 334724000 | Shares Floating 282348658 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 2 | Target Price 20.19 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Telix Pharmaceuticals Limited
Company Overview
History and Background
Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Founded in 2015, Telix has rapidly grown through acquisitions and strategic partnerships, with a focus on oncology.
Core Business Areas
- Diagnostic Imaging: Development and commercialization of radiopharmaceuticals for imaging various cancers, including prostate cancer, renal cancer, and glioblastoma.
- Therapeutic Products: Development of targeted radiotherapies designed to deliver radiation directly to cancer cells, minimizing damage to healthy tissue.
Leadership and Structure
Telix is led by CEO Christian Behrenbruch. The company has a global structure with operations in Australia, the US, Europe, and Japan. The board includes members with extensive experience in pharmaceuticals and finance.
Top Products and Market Share
Key Offerings
- Illuccix (Kit for the preparation of gallium (68Ga) gozetotide injection): A PSMA-targeting PET imaging agent for prostate cancer. Illuccix is Telix's lead commercial product, and is approved in the US, Australia and Canada. Competitors include Lantheus (LNTH) and Progenics Pharmaceuticals (acquired by Lantheus). Revenue data from this product is not publicly available in detail but it is considered to be a strong revenue driver.
- TLX250-CDx: An investigational imaging agent targeting carbonic anhydrase IX (CAIX) for clear cell renal cell carcinoma (ccRCC). Currently in clinical development. Main competitors are companies developing similar investigational agents in the renal cancer imaging space. Market Share data unavailable.
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing due to advancements in nuclear medicine and targeted therapies. Aging populations and increasing cancer incidence are driving demand. Growth is fueled by innovations in PET and SPECT imaging agents.
Positioning
Telix is positioned as a leader in the radiopharmaceutical space, focusing on oncology. Its competitive advantage lies in its proprietary technology platform and diverse pipeline of diagnostic and therapeutic products.
Total Addressable Market (TAM)
The total addressable market for radiopharmaceuticals in oncology is estimated to reach billions of dollars. Telix is positioned to capture a significant portion of this market with its approved and pipeline products. Market analysis estimates the global radiopharmaceuticals market to reach $8.31 Billion by 2033.
Upturn SWOT Analysis
Strengths
- Strong product pipeline focused on oncology
- Proprietary technology platform
- Experienced management team
- Global operations
- Established manufacturing and distribution network
Weaknesses
- Reliance on successful clinical trials and regulatory approvals
- Competition from larger pharmaceutical companies
- High R&D costs
- Manufacturing complexities associated with radiopharmaceuticals
Opportunities
- Expansion into new cancer indications
- Strategic partnerships and collaborations
- Increased adoption of radiopharmaceuticals in clinical practice
- Development of theranostic applications (combining diagnostics and therapeutics)
Threats
- Regulatory hurdles
- Competition from biosimilars
- Changes in reimbursement policies
- Supply chain disruptions for radioactive materials
Competitors and Market Share
Key Competitors
- LNTH
- BIPN
- AVEO
Competitive Landscape
Telix has a competitive advantage in specific oncology areas due to its targeted radiopharmaceutical approach. It competes with larger pharmaceutical companies and specialized radiopharmaceutical companies. Telix competes aggressively in the prostate cancer imaging market, leveraging the specificity and clinical utility of its products.
Major Acquisitions
TheraPharm GmbH
- Year: 2023
- Acquisition Price (USD millions): 12.8
- Strategic Rationale: To strengthen Telix's European presence and manufacturing capabilities for radiopharmaceuticals.
Growth Trajectory and Initiatives
Historical Growth: Telix has experienced rapid growth in recent years, driven by product approvals and commercial launches.
Future Projections: Future growth is projected to be driven by continued expansion of Illuccix, pipeline advancements, and potential acquisitions.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, initiating new clinical trials, and pursuing regulatory approvals in new markets.
Summary
Telix Pharmaceuticals is a rapidly growing biopharmaceutical company focused on oncology radiopharmaceuticals. With a strong product pipeline and expanding commercial presence, it is well-positioned to capitalize on the growing demand for targeted cancer therapies. However, the company faces risks related to clinical trials, regulatory approvals, and competition. Financial information on the company is not readily available, making the total market impact harder to measure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where available)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Financial figures may not be fully detailed due to limited public availability.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telix Pharmaceuticals Limited
Exchange NASDAQ | Headquaters North Melbourne, VIC, Australia | ||
IPO Launch date 2024-11-14 | Co-Founder, MD, Group CEO & Executive Director Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telixpharma.com |
Full time employees - | Website https://telixpharma.com | ||
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases. The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions. It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. The company's products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX007-CDx, a cold kit for the preparation of imaging for prostate cancer; TLX66-CDx to treat bone marrow conditioning. It also TLX250 for the treatment of clear cell renal cell carcinoma; TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning. In addition, the company develops TLX300 for the treatment of soft tissue sarcoma; TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX090, a bone-seeking agent for bone metastases and pain palliation. Further, it operates in Australia, New Zealand, Belgium, Japan, Switzerland, Germany, the United Kingdom, Canada, Singapore, Austria, Spain, France, and the United States. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.